ID: MRFR/MED/3879-HCR | 115 Pages | Published By Kinjoll Dey on March 2023
Dumping Syndrome Market Scenario
Th Dumping Syndrome Market is projected to reach USD 2,241.92 Million by 2030 at 9.40% CAGR during the forecast period 2022-2030.Dumping syndrome is a condition which develops after the surgery done to lose weight by removing all or part of the stomach. It is also called rapid gastric emptying and dumping syndrome, occurs when food especially sugar moves from the stomach into the small bowel too quickly. In some cases dumping syndrome occurs after gastric bypass surgery. According to the University of Rochester Medical Center, the dumping syndrome can happen in at least 3 out of 20 patients who have had a part of their stomach removed for any reason.
Mostly, people with dumping syndrome develop signs and symptoms, such as abdominal cramps and diarrhea, 10 to 30 minutes after eating. Whereas in some cases people have symptoms one to three hours after eating, few have also reported having both early and late symptoms. Early signs and symptoms include nausea, vomiting, abdominal cramps, diarrhea flushing, dizziness, lightheadedness, and rapid heart rate whereas, late signs and symptoms include sweating, hunger, fatigue, dizziness, lightheadedness, weakness, and rapid heart rate. The rising prevalence of upper GI diseases, changing lifestyle, and increasing demand for minimally invasive surgery are major drivers for the growth of the market across the globe. Additionally, use of technologically advanced devices for a surgical procedure in healthcare institutes also influence the market growth during the forecast period. Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries lead the globalization by pushing new products and services into the developing countries and emerging economies. On the other hand, side effects of dumping syndrome may hamper the market growth during the forecast period.
Figure: Global Dumping Syndrome Market, By Region Market Share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
The dumping syndrome market is segmented on the basis of diagnosis, treatment, and end user.
On the basis of diagnosis, dumping syndrome market is segmented into blood sugar test, gastric emptying test, medical history, and others.
Based on the treatment, dumping syndrome market is segmented into medication, surgery, and others. Medication is further sub-segmented into imodium, lomotil, prevalite, colestid, welchol, octreotide, and others.
On the basis of the end user, dumping syndrome market is segmented into hospitals & clinics, research laboratories, and others.
Some of key the players in the dumping syndrome market are Medtronic (U.S.), Intuitive Surgical Inc. (U.S.), TransEnterix Inc. (U.S.), ALLERGAN (Republic of Ireland), USGI Medical Inc. (U.S.), Cousin Biotech (France), GI Dynamics Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Mediflex Surgical Product (U.S.), and others.
Sources: Annual reports, Press release, White paper, and Company presentation
The Americas dominate the dumping syndrome market owing to increasing research & development activities and concentration of major market players boosting the market growth during the forecast period. Moreover, well-developed technology, increasing patient population with upper GI diseases, high healthcare spending, and increasing government support for research & development drive the market growth.
Europe holds the second position in the dumping syndrome market owing to the government support for research & development and availability of funds for research. For instance, countries like Germany and France are increasing investment in the healthcare domain. Furthermore, this is expected to continue to drive the European market over the forecasted period.
Asia Pacific is the fastest growing dumping syndrome market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods for gastrointestinal diseases in countries like India and China is likely to emerge as the fastest growing market across the globe. Moreover, increasing demand for quality devices in the healthcare sector is projected to lead to the use of advanced equipment, which in turn, is anticipated to increase the market growth in the region.
On the other hand, in the Middle East and Africa, limited market share due to gastrointestinal diseases have become a huge problem owing to limited screening, ignorance of diseases, and poor access to the treatment.
|Market Size||2030: USD 2,241.92 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment, and End user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Medtronic (U.S.), Intuitive Surgical Inc. (U.S.), TransEnterix Inc. (U.S.), ALLERGAN (Republic of Ireland), USGI Medical Inc. (U.S.), Cousin Biotech (France), GI Dynamics Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Mediflex Surgical Product (U.S.), and others|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Dumping syndrome market is projected to grow at a 9.40% CAGR between 2022- 2030.
The Americas is expected to dominate the dumping syndrome market.
Medical history, gastric emptying test, blood sugar test, and others are the different types of diagnosis for dumping syndrome.
Certain side effects may limit the dumping syndrome market growth.
Notable players profiled in the dumping syndrome market include Mediflex Surgical Product (U.S.), Johnson & Johnson Services, Inc. (U.S.), GI Dynamics Inc. (U.S.), Cousin Biotech (France), USGI Medical Inc. (U.S.), ALLERGAN (Republic of Ireland), TransEnterix Inc. (U.S.), Intuitive Surgical Inc. (U.S.), and Medtronic (U.S.).